Contraception with an injectable progestin

Mishell, Daniel R.; El-Habashy, Moustafa Aly; Good, Robert G.; Moyer, Dean L.

doi:10.1016/0002-9378(68)90346-3

Cited by 54 publications

(17 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Injection of a long-acting progestogen is an alternative to the implant, one that has long attracted interest. Mishell et al (1968) first reported results of a trial involving DMPA (depot medroxyprogesterone acetate). One hundred women were injected with 150 mg every three months.…”

Section: Evaluation Of Results Of Existing Studiesmentioning

confidence: 96%

“…Interpretation of this result is problematic, given the criteria for selection into the sample, for reasons given above for the combined pill. Implants and Injectables (Table 9) Evidence about the efficacy of long-acting progestogens in the form of an injectable or an implant comes only from clinical trials, since the drugs are not approved for Mishell et al, 1968 Depo-Provera 150 mg 100 0.Oc 59% aged 21-30 24.0c (90-day) Howard et al, 1982 Norigest 200 mg 383 0.0c 6.5" Britain (56-day) WHO, 1983 Depo-Provera 150 mg 1,587 0. (Sivin et al, 1983;Sivin, 1987a).…”

Section: Evaluation Of Results Of Existing Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Contraceptive Failure in the United States: A Critical Review of the Literature

Trussell

Kost²

1987

Studies in Family Planning

246

View full text Add to dashboard Cite

The overall goal of this paper is to provide for the first time a comprehensive critical review of the literature on contraceptive failure in developed countries, primarily the United States. The first two sections of our paper lay the groundwork for a critical assessment of the extensive body of studies on this subject, by systematically exploring the concepts and measurement of contraceptive efficacy and the methodological pitfalls that snare many investigators and compromise their results. The next two sections focus on results in the literature. First we provide a method-by-method critique of the available studies and then we summarize our conclusions in a single table that provides efficacy information necessary for women and couples to make an informed choice of a method of contraception. We close with a set of substantive observations and also a set of methodological recommendations intended to improve the quality and comparability of findings from future research.

show abstract

Section: Evaluation Of Results Of Existing Studiesmentioning

confidence: 96%

Section: Evaluation Of Results Of Existing Studiesmentioning

confidence: 99%

Contraceptive Failure in the United States: A Critical Review of the Literature

Trussell

Kost²

1987

Studies in Family Planning

246

View full text Add to dashboard Cite

show abstract

“…Toutefois, 18 mois après l'abandon, les taux cumulatifs de conception deviennent identiques, quelle que soit la méthode appliquée antérieurement. Selon Mishell et al [8], le taux des accouche ments prématurés, des avortements ou des anomalies congénitales n'est pas augmenté. La durée de la période infertile après l'abandon du Depo-Provera n'a aucun rapport avec sa durée d'utilisation.…”

Section: I^es Risques Génétiquesunclassified

“…Lorsque les hémorragies irrégulières après les premières injections sont trop importantes, il importe de pratiquer un curettage explorateur, qui, dans un cas de notre série, a révélé paradoxalement un endomètre prolifé ratif hyperplasique à tendance kystique! A propos des hémorragies, il faut rappeler avec Mishell et al [8], qu'elles sont plus fréquentes lorsque le Depo-Provera est administré dans le post partum immédiat.…”

Section: Le Cancer De L 'Endomètreunclassified

Risques vrais et faux de la contraception hormonale injectable

Revaz¹

1984

Gynäkol Geburtshilfliche Rundsch

View full text Add to dashboard Cite

“…Selon Mishell et al (12), le taux des accouchements prématurés, des avortements ou des anomalies congénitales n'est pas augmenté. La durée de la période infertile après l'abandon du Depo-Provera n'a aucun rapport avec sa durée d'utilisation.…”

Section: )unclassified